Oncology biotech Monopar Therapeutics sets terms for $40 million IPO
Monopar Therapeutics, a Phase 3 biotech developing therapies for various types of cancer, announced terms for its IPO on Tuesday.
The Wilmette, IL-based company plans to raise $40 million by offering 4.4 million shares at a price range of $8 to $10. At the midpoint of the proposed range, Monopar Therapeutics would command a fully diluted market value of $130 million.
Monopar Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol MNPR. JonesTrading is the sole bookrunner on the deal.
The article Oncology biotech Monopar Therapeutics sets terms for $40 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
Latest IPOs Videos
- US IPO Week Ahead: The September IPO calendar stays Good(Rx) and busy in an 8 IPO week
- Let it SNOW: Data unicorn Snowflake prices $3.4 billion IPO above the range at $120 in largest software listing ever
- US IPO Week Ahead: The IPO market braces for a September SNOWstorm in a 14 IPO week
- The SNOWstorm gets bigger: Snowflake increases range to $100 to $110 ahead of $2.9 billion IPO